Drug profile · INN
human normal immunoglobulin
HYQVIA
human normal immunoglobulin (HYQVIA) is a replacement therapy, immunomodulatory effects. Associated with Takeda.
EMA: approved Antiinfectives for systemic use (J06) J06BA01
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — human normal immunoglobulin
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.89
Quick answer
human normal immunoglobulin (HYQVIA) is a replacement therapy, immunomodulatory effects. Associated with Takeda.
Key facts
INN human normal immunoglobulin
Brand HYQVIA
Mechanism Replacement therapy, immunomodulatory effects
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BA01
Originator Takeda
Mechanism of action
Replacement therapy, immunomodulatory effects
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is human normal immunoglobulin?
human normal immunoglobulin (HYQVIA) is a replacement therapy, immunomodulatory effects. Associated with Takeda.
What is the brand name for human normal immunoglobulin?
HYQVIA is a marketed brand name for human normal immunoglobulin. Check FDA Drugs@FDA for the current US label holder and prescribing information.